Christopher Towler

OBS Medical Ltd. manufactures and distributes physiological monitoring and patient monitoring devices. Its product Visensia, a physiological monitoring system for detecting early clinical patient deterioration. The firm operates as a predictive software company that provides products and services for the hospital, community and consumer health care markets. It develops and support products that enable their customers, both patients and healthcare professionals, to manage and monitor health conditions more effectively through simplification, risk identification and prevention. The company was founded in 2000 and is headquartered in Abingdon, the United Kingdom.

Chronos Therapeutics Ltd. manufactures drugs. It pursuing innovative therapeutics for age-related diseases through the joint efforts of experts in medical research, drug discovery and business development. The company was founded in 2009 and is headquartered in Oxford, the United Kingdom.

Oxford Spin-out Equity Management (OSEM) is wholly-owned subsidiary of University of Oxford. The firm headquartered at UK. Since 2008, OSEM is responsible for spinout companies.

Alcolizer Technology United Kingdom Ltd. produces drug testing kits. It offers a device used in detecting whether a person in under the influence of specific drugs. The company was founded by Craig Edward Banks and Richard G. Compton on September 26, 2006 and is headquartered in Gateshead, the United Kingdom.

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.

Oxtex Ltd. operates as an early-stage medical device company. It develops novel devices for soft tissue expansion. The firm's technology comprises implantable self-inflating tissue expanders available in sizes and shapes to suit the specific needs of the clinician and the patient. The company was founded by Jan Tadeusz Czernuszka and David Edward Jackson in May 2011 and is headquartered in Witney, the United Kingdom.